{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00023198", "CSN": null, "TRF": "ORD_1452967_01", "MRN": "43192832", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1194220", "clinicalId": "1195590", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1452967_01", "SampleName": "US1393440.01", "Version": "0", "Sample": {"FM_Id": "ORD_1452967_01", "SampleId": "US1393440.01", "BlockId": "S111-29028A", "TRFNumber": "ORD_1452967_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_09_10", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "20", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97906", "MRN": "43192832", "FullName": "\u674e\u6dfb\u821c", "FirstName": "Tien_Shun", "LastName": "Li", "SubmittedDiagnosis": "Adenocarcinoma, Stomach", "Gender": "Male", "DOB": "1953_05_05", "OrderingMD": "\u6d2a\u9038\u5e73", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Stomach", "CollDate": "2022_07_29", "ReceivedDate": "2022-09-27 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Gastric Cancer"}, "PertinentNegatives": {"PertinentNegative": {"Gene": "ERBB2"}}, "Summaries": {"alterationCount": "21", "clinicalTrialCount": "15", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "AKT3", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "ALK", "isVUS": "true", "variantName": "D605N"}, {"geneName": "CBL", "isVUS": "true", "variantName": "R506Q"}, {"geneName": "FANCC", "isVUS": "true", "variantName": "P248R"}, {"geneName": "NKX2_1", "isVUS": "true", "variantName": "G322S"}, {"geneName": "NTRK3", "isVUS": "true", "variantName": "A380S"}, {"geneName": "PARP3", "isVUS": "true", "variantName": "R379Q"}, {"geneName": "PIK3C2G", "isVUS": "true", "variantName": "amplification"}, {"geneName": "PTCH1", "isVUS": "true", "variantName": "E44G,R1303C"}, {"geneName": "SUFU", "isVUS": "true", "variantName": "P482L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). In numerous cancer type_specific studies as well as a large_scale pan_cancer analysis, KRAS amplification was shown to correlate with increased expression (McIntyre et al., 2005; 16354586, Mita et al., 2009; 19545448, Birkeland et al., 2012; 23099803, Chen et al., 2014; 24874471). Additionally, KRAS amplification correlated with sensitivity of cancer cell lines to KRAS knockdown, suggesting that amplified KRAS is an oncogenic driver (Chen et al., 2014; 24874471). Amplification of KRAS has been found in up to 6% of stomach adenocarcinoma cases (Cancer Genome Atlas Research Network., 2014; 25079317, cBio_Wang et al., 2014; 24816253, cBio_Kakiuchi et al., 2014; 24816255, cBio_Wang et al., 2011; 22037554, Mita et al., 2009; 19545448). KRAS alterations, including mutations (Warneke et al., 2013; 23846438) and amplification (Wong et al., 2018; 29808010, Qian et al., 2014; 24935174, Deng et al., 2012; 22315472, Henderson et al., 2016; DOI: 10.1200/jco.2016.34.4_suppl.74) are associated with worse prognosis in patients with gastroesophageal cancer. One study reported that KRAS alteration did not significantly associate with OS in a cohort of patients with gastric, esophageal, or gastroesophageal adenocarcinoma (Kato et al., 2018; 30348637). Published data investigating the prognostic implications of KRAS alterations in esophageal squamous cell carcinoma are limited (PubMed, Sep 2022). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). Clinical evidence that KRAS amplification in the absence of a concurrent KRAS activating mutation is sensitive to MEK inhibitors is limited. A Phase 2 study of selumetinib plus docetaxel in patients with gastric cancer reported 1/2 patients with KRAS amplification experienced a PR (Lee et al., 2018; ASCO Abstract 4061). A patient with cervical cancer harboring both KRAS and PIK3CA amplification treated with the combination of trametinib and the AKT inhibitor GSK2141795 achieved a SD (Lui et al., 2019; 31118140).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03281369", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT04720976", "Include": "true"}, {"nctId": "NCT04965818", "Include": "true"}, {"nctId": "NCT04214418", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MDM2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "MDM2 encodes an E3 ubiquitin protein ligase, which mediates the ubiquitination and subsequent degradation of p53, Rb1, and other proteins (Sdek et al., 2005; 16337594, Brady et al., 2005; 15632057, Li et al., 2004; 15053880). MDM2 acts to prevent the activity of the tumor suppressor p53; therefore, overexpression or amplification of MDM2 may be oncogenic (Brown et al., 2009; 19935675, Cordon_Cardo et al., 1994; 8306343). Overexpression or amplification of MDM2 is frequent in cancer (Beroukhim et al., 2010; 20164920). Although two retrospective clinical studies suggest that MDM2 amplification may predict a short time_to_treatment failure on anti_PD_1/PD_L1 immune checkpoint inhibitors, with 4/5 patients with MDM2 amplification (Kato et al., 2017; 28351930) and 2/3 patients with MDM2 or MDM4 amplification (Singavi et al., 2017; ESMO Abstract 1140PD) experiencing tumor hyperprogression, amplification of MDM2 or MDM4 was not associated with shorter progression_free survival (PFS) in a retrospective analysis of non_small cell lung cancer (NSCLC) outcomes with immune checkpoint inhibitors (hazard ratio of 1.4, p=0.44)(Rizvi et al., 2018; 29337640). The latter study reported PFS of >2 months for 5/8 patients with MDM2/MDM4 amplification (Rizvi et al., 2018; 29337640). MDM2 amplification has been reported in 4.2% of stomach adenocarcinomas (cBio_Cancer Genome Atlas Research Network., 2014; 25079317), 3.7_5.2% of esophageal adenocarcinomas (cBio_Cancer Genome Atlas Research Network., 2017; 28052061, cBio_Janjigian et al., 2018; 29122777), and 12.3% (7/57) of gastroesophageal junction carcinomas (cBio_Janjigian et al., 2018; 29122777). MDM2 amplification has been reported in a small number of esophageal squamous cell carcinomas (SCCs); however, MDM2 overexpression has been reported more frequently (Tani\u00e8re et al., 2000; 11004672, Hsu et al., 2011; 21080085, Taghavi et al., 2010; 20388212, Cheng et al., 2009; 19488782). MDM2 overexpression has been reported to be associated with tumor stage and lymph node metastasis in gastric cardia adenocarcinoma (GCA) tumors, and was associated with differentiation in distal gastric adenocarcinoma (DGA) tumors (Yao et al., 2013; 23159155). Additionally, high MDM2 expression has been associated with poor overall survival in patients with gastric cancer (Ye et al., 2013; 23347235). In separate studies, amplification and over_expression of MDM2 has been identified in up to 42% of gastric carcinomas and has also been associated with Helicobacter pylori_related gastric cancer (G\u00fcnther et al., 2000; 10874665, Yang et al., 2012; 22306053). MDM2 antagonists disrupt the MDM2_p53 interaction, thereby stabilizing p53 (Cheok et al., 2011; 20975744). Preclinical studies have suggested that the amplification of MDM2, in the absence of concurrent TP53 mutations, may increase sensitivity to these agents (Ohnstad et al., 2013; 23165797, Gamble et al., 2012; 21725357). Preliminary Phase 1 studies of the MDM2_p53 antagonist alrizomadlin (APG_115) reported a PR in a patient with liposarcoma harboring an MDM2 amplification and wildtype for TP53 and SD in 21%\u201338% (6/28 and 5/13, respectively) of patients in genomically unselected solid tumors (Zhang et al., 2019; ASCO Abstract 3124, Rasco et al., 2019; ASCO Abstract 3126). A Phase 2 trial of alrizomadlin in combination with pembrolizumab reported a PR in 1 of 3 patients with malignant peripheral nerve sheath tumor that had failed standard therapy, as well as PRs in patients with multiple types of solid tumors that had failed immunotherapy, including 1 out of 14 patients with non_small cell lung cancer; 1 out of 5 patients with urothelial carcinoma; and 2 out of5, 1 out of 5, and 1 out of 11 patients with mucosal, uveal, and cutaneous melanoma, respectively (Tolcher et al., 2021; ASCO Abstract 2506). Phase 1b studies of the MDM2 inhibitor idasanutlin for refractory AML in combination with cytarabine or venetoclax reported anti_leukemic response rates of 33% (25/75) and 37% (11/30), respectively (Martinelli et al., 2016; EHA21 Abstract S504, Daver et al., 2018; ASH Abstract 767); clinical benefit (58% ORR, 7/12) with idasanutlin monotherapy has been reported for patients with polycythemia vera (Mascarenhas et al., 2019; ASH Abstract 134). The dual MDM2/MDM4 inhibitor ALRN_6924 led to an ORR of 27% (4/15) for patients with TP53 wildtype peripheral T_cell lymphoma in a Phase 2 study (Shustov et al., 2018; ASH Abstract 1623); responses have also been observed in TP53 wildtype AML, MDS, Merkel cell carcinoma, colorectal cancer, and liposarcoma (Sallman et al., 2018; ASH Abstract 4066, Meric_Bernstam et al., 2017; ASCO Abstract 2505).", "Include": "true", "ClinicalTrialNote": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04785196", "Include": "true"}, {"nctId": "NCT03611868", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MTAP", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 3_8", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 3_8"}}, "Interpretation": "MTAP encodes S_methyl_5 _thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity (Limm et al., 2016; 27479139, Tang et al., 2014; 25387827). Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment (Kirovski et al., 2011; 21356366, Limm et al., 2013; 23265702, Stevens et al., 2009; 19097084), thereby reducing intracellular arginine methylation (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360) and altering cell signaling (Limm et al., 2014; 25087184, Stevens et al., 2009; 19097084). MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co_deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized. MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers (Wei et al., 2016; 27929028, Zhao and Zhao, 2016; 27556634); such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma (Kirovski et al., 2011; 21356366), gastrointestinal stromal tumors (Huang et al., 2009; 19887491), mantle cell lymphoma (MCL)(Marce et al., 2006; 16778103), melanoma (Meyer et al., 2010; 20500769, Wild et al., 2006; 16618867), gastric cancer (Kim et al., 2011; 21412930), myxofibrosarcoma (Li et al., 2014; 25426549), nasopharyngeal carcinoma (He et al., 2015; 26656376), ovarian carcinoma (Wei et al., 2016; 27929028) and non_small cell lung cancer (Su et al., 2014; 24969958). MTAP loss was not prognostic in pediatric B_cell acute lymphocytic leukemia (Mirebeau et al., 2006; 16818274) or in astrocytoma (Becker et al., 2015; 26088413). However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples (Snezhkina et al., 2016; 27433286), and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM (Bistulfi et al., 2016; 26910893). Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma (Antonopoulou et al., 2015; 25407435, Mccioni et al., 2013; 23816148), esophageal cancer (Hyland et al., 2016; 26635288, Lin et al., 2017; 27960044), osteosarcoma (Zhi et al., 2016; 27994653), and CRC (Gu et al., 2013; 23361049). MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A (Kalev et al., 2021; 33450196, Heist et al., 2019; AACR_NCI_EORTC Abstract B116, Marjon et al., 2016; 27068473) or PRMT5 inhibition (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360). A Phase 1 trial of MAT2A inhibitor AG_270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss (Heist et al., 2019; AACR_NCI_EORTC Abstract B116). Preclinical data suggest that MTAP loss sensitizes cells to S_adenosyl_L_methionine (SAM)_competitive PRMT5 inhibitors (Guccione and Richard, 2019; 31350521), dual PRMT1 and PRMT5 inhibitors (Fedoriw et al., 2019; 31257072, Srour et al., 2019; 31287990, Gao et al., 2019; 30916320), and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S_methyl_5 _thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193 (Smith et al., 2022; 35041419, Briggs et al., 2022; AACR Abstract 3941). In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA (Hansen et al., 2019; 31040154, Tang et al., 2018; 29844120, Munshi et al., 2014; 24928612, de Oliveira et al., 2016; 26751376, Lubin and Lubin, 2009; 19478948, Tang et al., 2012; 22825330, Collins et al., 2012; 22252602, Bertino et al., 2011; 21301207, Coulthard et al., 2011; 21282358, Miyazaki et al., 2007; 17912432, Efferth et al., 2002; 11987241). A Phase 2 study of L_alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP_deficient cancers reported no responses and SD for 24% (13/55) of patients (Kindler et al., 2009; 18618081). Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed (Alhalabi et al., 2022; 35379845).", "Include": "true", "ClinicalTrialNote": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT05094336", "Include": "true"}, {"nctId": "NCT05245500", "Include": "true"}, {"nctId": "NCT05275478", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Loss of the 9p21 region that encompasses the CDKN2A/CDKN2B locus has been observed in 24_67% of esophageal squamous cell carcinoma (ESCC)(Xing et al., 1999; 10537333, Hao et al., 2012; 22920630, Rumiato et al., 2011; 21757289, Kim et al., 2006; 17060721, Liu et al., 1995; 7845688, Muzeau et al., 1997; 9212218, Chen et al., 2008; 18241037, Hayashi et al., 1997; 9333024), and 26_37% of esophageal adenocarcinoma samples, and is thought to be a critical step in the progression of Barrett esophagus to adenocarcinoma (Koppert et al., 2005; 16299787, cBio_Dulak et al., 2013; 23525077, Bandla et al., 2012; 22450065, Nancarrow et al., 2008; 18519675). In the Stomach Adenocarcinoma TCGA dataset, concurrent putative homozygous deletion of both CDKN2A and CDKN2B has been reported in 10% of cases (Cancer Genome Atlas Research Network., 2014; 25079317). In gastric cancer, methylation of CDKN2A and CDKN2B has been reported in 67% of cases and hypermethylation or deletion of CDKN2A alone has been reported in 20_72% of cases (Xiong et al., 2013; 23803092, Lee et al., 2002; 12060614, Alves et al., 2011; 21849808, Shi et al., 2012; 22206050, He et al., 2001; 11819820, Tang et al., 2003; 12890389). Expression of p16INK4a has been shown to decrease during gastric cancer tumorigenesis, detected in 96% of normal gastric tissue, 92% of dysplastic gastric mucosa, and 48% of gastric carcinoma samples (He et al., 2001; 11819820). One study found that expression of p14ARF decreases during disease progression in esophageal adenocarcinoma, with 75% (57/76) of samples having no detectable p14ARF expression; moreover, expression of p14ARF strongly correlated with increased survival (Huang et al., 2009; 18410530). Loss or downregulation of p15INK4b and p16INK4a expression has been reported in ESCC tumor samples and correlated with downregulation of TGFBR2, increased inflammation, and increased DNA damage (Achyut et al., 2013; 23408900). In addition, loss of p16INK4a, but not p15INK4b, has been associated with tumor progression and poor prognosis in patients with ESCC (Tokugawa et al., 2002; 12208744, Fujiwara et al., 2008; 18269647, Chen et al., 2008; 18241037, Xing et al., 1999; 10537333, Hao et al., 2012; 22920630). Inactivation of CDKN2A and CDKN2B by promoter methylation has been linked with poor survival in patients with gastric cancer (Shi et al., 2012; 22206050). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Loss of the 9p21 region that encompasses the CDKN2A/CDKN2B locus has been observed in 24_67% of esophageal squamous cell carcinoma (ESCC)(Xing et al., 1999; 10537333, Hao et al., 2012; 22920630, Rumiato et al., 2011; 21757289, Kim et al., 2006; 17060721, Liu et al., 1995; 7845688, Muzeau et al., 1997; 9212218, Chen et al., 2008; 18241037, Hayashi et al., 1997; 9333024), and 26_37% of esophageal adenocarcinoma samples, and is thought to be a critical step in the progression of Barrett esophagus to adenocarcinoma (Koppert et al., 2005; 16299787, cBio_Dulak et al., 2013; 23525077, Bandla et al., 2012; 22450065, Nancarrow et al., 2008; 18519675). In the Stomach Adenocarcinoma TCGA dataset, concurrent putative homozygous deletion of both CDKN2A and CDKN2B has been reported in 10% of cases (Cancer Genome Atlas Research Network., 2014; 25079317). In gastric cancer, methylation of CDKN2A and CDKN2B has been reported in 67% of cases and hypermethylation or deletion of CDKN2A alone has been reported in 20_72% of cases (Xiong et al., 2013; 23803092, Lee et al., 2002; 12060614, Alves et al., 2011; 21849808, Shi et al., 2012; 22206050, He et al., 2001; 11819820, Tang et al., 2003; 12890389). Expression of p16INK4a has been shown to decrease during gastric cancer tumorigenesis, detected in 96% of normal gastric tissue, 92% of dysplastic gastric mucosa, and 48% of gastric carcinoma samples (He et al., 2001; 11819820). One study found that expression of p14ARF decreases during disease progression in esophageal adenocarcinoma, with 75% (57/76) of samples having no detectable p14ARF expression; moreover, expression of p14ARF strongly correlated with increased survival (Huang et al., 2009; 18410530). Loss or downregulation of p15INK4b and p16INK4a expression has been reported in ESCC tumor samples and correlated with downregulation of TGFBR2, increased inflammation, and increased DNA damage (Achyut et al., 2013; 23408900). In addition, loss of p16INK4a, but not p15INK4b, has been associated with tumor progression and poor prognosis in patients with ESCC (Tokugawa et al., 2002; 12208744, Fujiwara et al., 2008; 18269647, Chen et al., 2008; 18241037, Xing et al., 1999; 10537333, Hao et al., 2012; 22920630). Inactivation of CDKN2A and CDKN2B by promoter methylation has been linked with poor survival in patients with gastric cancer (Shi et al., 2012; 22206050). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_H tumors reportedly make up 12_35% of sporadic gastric cancers (Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086, Cancer Genome Atlas Research Network, 2017; 28052061). In the context of diffuse_type gastric cancer, a higher frequency of MSI_H tumors has been reported in familial (28%, 7/25) versus sporadic (7%, 7/107) tumors; no difference in frequency of MSI_H tumors was observed for intestinal_type gastric cancer (Fang et al., 2013; 23555086). MSI_H tumors have been frequently associated with hypermethylation and loss of MLH1 expression in cancers of the upper gastrointestinal tract, including esophageal, gastroesophageal junction, and gastric adenocarcinomas (Fang et al., 2013; 23555086, Gu et al., 2009; 19621725, Sasaki et al., 2011; 22866067, Fleisher et al., 1999; 10070967, Vasavi et al., 2010; 21045259, Zhang et al., 2013; 24035280). MSI_H gastric cancers are associated with certain clinicopathological and molecular features, including intestinal type differentiation, antral location, advanced age, reduced lymph node metastasis, and better prognosis (Zhu et al., 2015; 26137290, Leung et al., 1999; 9892201, dos Santos et al., 1996; 8536886, Wu et al., 1998; 9537253, Seo et al., 2015; 26078567, Cancer Genome Atlas Research Network., 2014; 25079317). A retrospective meta_analysis of the prognostic role of MSI in gastric cancers reported an increased DFS and OS in patients with MSI_H versus MSS/MSI_Low (Pietrantonio et al., 2019; 31513484). Conversely, in the same study, MSI_H was a negative predictor of response and MSS/MSI_Low correlated with increased benefit for patients treated with chemotherapy plus surgery as opposed to surgery alone (Pietrantonio et al., 2019; 31513484). In gastroesophageal cancer, MSI_H status was associated with shorter PFS compared to MSS patients for patients treated with chemotherapy (mPFS 4.8 months vs 6.9 months, HR=0.4) (Janjigian et al., 2018; 29122777). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "SMAD4", "Include": "true", "Alterations": {"Alteration": {"Name": "loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss"}}, "Interpretation": "SMAD4, also known as DPC4, encodes a tumor suppressor that regulates transcriptional activity downstream of TGF_beta receptor signaling (Massague et al., 2012; 22992590, Massague et al., 2008; 18662538). SMAD4 alterations that result in loss or disruption of the MH1 domain (aa 18_142), MH2 domain (aa 323_552), or SAD domain (aa 275_320) are predicted to be inactivating (Massague et al., 2005; 16322555, Mor\u00e9n et al., 2000; 10980615, Xu and Attisano, 2000; 10781087, Luo et al., 1999; 10485843, Jones and Kern, 2000; 10871368, Fink et al., 2001; 11196171, De Bosscher et al., 2004; 14715079, Shi et al., 1997; 9214508, Miyaki et al., 1999; 10340381, Prokova et al., 2007; 17994767, Wu et al., 2001; 11274206, Ding et al., 2009; 19139564, Kuang et al., 2004; 14647410, Watanabe et al., 2000; 11265759, Bosscher et al., 2004; 14715079). SMAD4 mutation or homozygous deletion is most frequently observed in pancreatic adenocarcinoma (43%)(cBio_Witkiewicz et al., 2015; 25855536), pancreatic acinar cell carcinoma (26%)(Jiao et al., 2014; 24293293), cholangiocarcinoma (25%)(Churi et al., 2014; 25536104), small intestine cancer (20%) (Takeda et al., 2022; ASCO GI Abstract 642), appendiceal adenocarcinoma (14_20% mutation; 57% deletion)(Liu et al., 2014; 24821835, Maru et al., 2004; 14647445), colorectal adenocarcinoma (CRC; 14%)(Cancer Genome Atlas Network., 2012; 22810696), esophageal adenocarcinoma (14%)(Wang et al., 2015; 26336083), and stomach adenocarcinoma (13%)(Cancer Genome Atlas Research Network., 2014; 25079317). In preclinical studies, SMAD4 loss of function has been implicated in the development of mucinous neoplasms of the pancreas, including mucinous cystic neoplasms (MCN)(Izeradjene et al., 2007; 17349581) and intraductal papillary mucinous neoplasms (IPMN)(Bardeesy et al., 2006; 17114584); in clinical samples, SMAD4 homozygous deletion has been observed in 10% of IPMNs and 8% of MCNs, and mutation was also observed in 5% of IPMNs (Springer et al., 2015; 26253305). SMAD4 gene alterations have been associated with reduced overall survival for patients with pancreatic adenocarcinoma (Blackford et al., 2009; 19584151). Reduced SMAD4 expression has been associated with worse prognosis in various cancer types, including CRC (Yan et al., 2016; 26861460, Kozak et al., 2015; 25681512, Roth et al., 2012; 23104212), appendiceal mucinous neoplasm (Davison et al., 2014; 24618609), gastric adenocarcinoma (Kim et al., 2004; 15033661, Xiangming et al., 2001; 11234879), esophageal adenocarcinoma (Singhi et al., 2015; 25634752), esophageal squamous cell carcinoma (Natsugoe et al., 2002; 12060625), breast cancer (de Kruijf et al., 2013; 23022998), and prostate cancer (Shipitsin et al., 2014; 25032733). There are no targeted therapies available to address genomic alterations in SMAD4. Preclinical studies in colorectal cancer have reported associations of SMAD4 inactivation or loss with sensitivity to inhibitors of Aurora kinase A (Shi et al., 2022; 35393542) and the Wnt/beta_catenin pathway (Park et al., 2022; 35274815). Clinical studies have reported associations of SMAD4 loss or low SMAD4 expression with improved responses to chemotherapeutic agents in patients with pancreatic cancer (Ormanns et al., 2017; 28534865, Fei et al., 2021; 34002944, Bachet et al., 2012; 22377565) and non_small cell lung cancer (NSCLC) (Ziemke et al., 2017; 28577946). Other clinical studies in pancreatic cancer have reported an association of high SMAD4 expression with better responses to neoadjuvant chemotherapy (Kassardjian and Wang, 2020; 32897998) and adjuvant chemoradiotherapy (Pen et al., 2021; 33667587). Germline SMAD4 mutations, including those at the R361 hotspot, have been observed in patients with juvenile polyposis syndrome (Houlston et al., 1998; 9811934, Woodford_Richens et al., 2000; 10764709, Howe et al., 2004; 15235019, Howe et al., 2004; 15235019, Howe et al., 2004; 15235019), which is associated with an increased risk of gastrointestinal cancers (Brosens et al., 2011; 22171123). The penetrance of deleterious SMAD4 mutations in patients with colon cancer is estimated at 20% by age 35 and 70% by age 65 (Kalia et al., 2017; 27854360). In the appropriate clinical context, germline testing of SMAD4 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "S261N", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S261N"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 is frequently mutated in cancers of the gastrointestinal tract, with alterations reported in 34\u201372% of esophageal, gastroesophageal junction, and gastric adenocarcinomas (Dulak et al., 2013; 23525077, Cancer Genome Atlas Research Network., 2014; 25079317, Sengpiel et al., 2009; 19160092, P\u00fchringer_Oppermann et al., 2006; 16538517). Overexpression of p53 protein, which may occur as a result of mutation, has been reported in approximately 36% of gastric cancers, with p53 expression reported to be more frequent in intestinal_type compared with diffuse_type gastric cancer (Lee et al., 2014; 23969480, Sezer et al., 2013; 23613399, Victorzon et al., 1996; 8664030, Gon\u00e7alves et al., 2011; 21116760). While some studies have reported no association between TP53 mutation status and prognosis in patients with esophageal carcinoma or gastroesophageal junction adenocarcinoma (Sengpiel et al., 2009; 19160092, P\u00fchringer_Oppermann et al., 2006; 16538517) others have associated TP53 mutation and elevated p53 expression with poor prognosis for patients with esophageal squamous cell carcinoma (Han et al., 2007; 17760650, Yamasaki et al., 2010; 19941080) or stomach cancer (Liu et al., 2012; 23285001, Wiksten et al., 2008; 18751407, Migliavacca et al., 2004; 15254976). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Gastric adenocarcinoma harbors a median TMB of 3.6 mutations per megabase (muts/Mb), and 5.5% of cases have high TMB (>20 muts/Mb) (FMI_Chalmers et al., 2017; 28420421). However, one study reported high TMB in 20% of intestinal type stomach adenocarcinomas specifically (Frampton et al., 2016; ASCO Abstract 11558). Another study of patients with gastric cancer reported hypermutation (10_200 muts/Mb) in 16.4% of cases, with significant overrepresentation of samples with microsatellite instability among the hypermutant cases (Li et al., 2016; 26857262). For patients with gastric cancer, increased TMB is reported to be associated with prolonged OS (Cai et al., 2020; 32141230, Zhao et al., 2021; 33510848, Wei et al., 2021; 33613701). One study observed that the OS and disease_free survival (DFS) benefits of postoperative chemotherapy were more pronounced in patients with TMB_low gastric cancer (stage Ib/II) compared to those with TMB_high; however, patients with stage III gastric cancer benefitted regardless of TMB level (Wang et al., 2021; 33687617). In esophageal cancer, patients with TMB_high who had not received radiotherapy had significantly reduced OS (p=0.038) compared to those with TMB_low (Yuan et al., 2019; 32165590). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "ZNF217", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "ZNF217 encodes a candidate oncogene that has likely roles in histone modification and transcriptional repression (Huang et al., 2005; 16203743, Banck et al., 2009; 19242095). ZNF217 amplification has been correlated with protein overexpression in breast carcinoma tumors and cell lines (Collins et al., 1998; 9671742). The role of ZNF217 in promoting tumorigenesis was established in preclinical studies demonstrating that expression of ZNF217 results in the immortalization of both human mammary epithelial cells and ovarian surface epithelial cells in culture (Nonet et al., 2001; 11245413, Li et al., 2007; 17266044). Amplification and/or overexpression of ZNF217 has been reported in breast (Vendrell et al., 2012; 22593193), ovarian (Li et al., 2014; 25031722, Rahman et al., 2012; 22843878), gastric (Yang et al., 2005; 15701848, Shida et al., 2014; 25202062), colon (Rooney et al., 2004; 15476264), prostate (Szczyrba et al., 2012; 22815235), esophageal (Geppert et al., 2014; 24853183), and urothelial carcinomas (Toncheva et al., 2005; 15897688), glioblastoma (Mao et al., 2011; 21483406), and ovarian carcinosarcomas (Schipf et al., 2008; 18193277). Overexpression in these tumors has generally been linked with aggressive tumor behavior and poor clinical prognosis. High levels of ZNF217 expression result in dysregulation of a broad range of genes that may contribute to tumorigenesis (Quinlan et al., 2007; 17572303, Krig et al., 2007; 17259635, Cowger et al., 2007; 17130829), and increased expression or activation of ERBB3 (Krig et al., 2010; 20661224, Vendrell et al., 2012; 22593193), FAK (Vendrell et al., 2012; 22593193), Aurora kinase A (Thollet et al., 2010; 21059223), AKT (Huang et al., 2005; 16203743), and TGF_beta/SMAD signaling (Vendrell et al., 2012; 22593193) has been demonstrated in ZNF217_expressing tumors or cells. There are no available targeted therapies to address genomic alterations in ZNF217. Expression of ZNF217 may predict relapse of estrogen receptor (ER)_positive breast cancer under hormone therapy through its direct interaction with ER_alpha (Nguyen et al., 2014; 24973012, Frietze et al., 2014; 24962896). ZNF217 overexpression has also been associated with resistance to paclitaxel (Thollet et al., 2010; 21059223) and doxorubicin (Huang et al., 2005; 16203743) in breast cancer cell lines. ZNF217 has been suggested as a potential biomarker for treatment with the DNA synthesis inhibitor and AKT inhibitor triciribine in breast cancer based on preclinical findings in cultured cells and xenografts expressing high levels of ZNF217; triciribine treatment also restored sensitivity to doxorubicin in these cells (Littlepage et al., 2012; 22728437).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "amplification", "Title": "A Study of Multiple Immunotherapy_Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus_Gastric Cancer)", "StudyPhase": "PHASE 1/2", "Target": "MEK, CXCR4, VEGFRs, PD_L1", "Locations": "Taipei City (Taiwan), Zhongzheng Dist. (Taiwan), Tainan (Taiwan), Suwon_si, (Korea, Republic of), Seoul (Korea, Republic of), Seodaemun_Gu (Korea, Republic of), Songpa_gu (Korea, Republic of), Blacktown (Australia), Melbourne (Australia), Clayton (Australia)", "NCTID": "NCT03281369", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs", "StudyPhase": "PHASE 2", "Target": "BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6", "Locations": "Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT05159245", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas", "NCTID": "NCT03905148", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "JAB_3312 Activity in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MEK, SHP2, PD_1, EGFR, KRAS", "Locations": "Utah", "NCTID": "NCT04720976", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer", "StudyPhase": "PHASE 1/2", "Target": "MEK, FGFRs", "Locations": "California, Indiana, Texas", "NCTID": "NCT04965818", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "amplification", "Title": "Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS_mutated Advanced Malignancies", "StudyPhase": "PHASE 1/2", "Target": "PD_L1, MEK", "Locations": "Rhode Island, New York", "NCTID": "NCT04214418", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "APG_115 in Combination With PD_1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_1, MDM2", "Locations": "Shanghai (China), Guangzhou (China)", "NCTID": "NCT04785196", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "A Study of APG_115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MDM2, PD_1", "Locations": "Brisbane (Australia), South Brisbane (Australia), Bedford Park (Australia), Heidelberg (Australia), California, Arizona, Missouri, Arkansas, Ohio, Pennsylvania", "NCTID": "NCT03611868", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss exons 3_8", "Title": "AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)_Null Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Nagoya_shi (Japan), Chuo_ku (Japan), Kashiwa_shi (Japan), Camperdown (Australia), Halle (Saale) (Germany), Salzburg (Austria), W\u00fcrzburg (Germany), Ulm (Germany), Edegem (Belgium), Bruxelles (Belgium)", "NCTID": "NCT05094336", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss exons 3_8", "Title": "Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Colorado, Massachusetts, New York, Tennessee, Texas", "NCTID": "NCT05245500", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss exons 3_8", "Title": "Safety and Tolerability of TNG908 in Patients With MTAP_deleted Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Massachusetts, Tennessee, Texas, Virginia", "NCTID": "NCT05275478", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "16337594", "FullCitation": "Sdek P, et al. Mol. Cell (2005) pmid: 16337594", "Include": "true"}, {"number": "1", "ReferenceId": "15632057", "FullCitation": "Brady M, et al. Mol. Cell. Biol. (2005) pmid: 15632057", "Include": "true"}, {"number": "2", "ReferenceId": "15053880", "FullCitation": "Li M, et al. Mol. Cell (2004) pmid: 15053880", "Include": "true"}, {"number": "3", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "4", "ReferenceId": "8306343", "FullCitation": "Cordon_Cardo C, et al. Cancer Res. (1994) pmid: 8306343", "Include": "true"}, {"number": "5", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "6", "ReferenceId": "28351930", "FullCitation": "Kato S, et al. Clin. Cancer Res. (2017) pmid: 28351930", "Include": "true"}, {"number": "7", "ReferenceId": "29337640", "FullCitation": "Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640", "Include": "true"}, {"number": "8", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "9", "ReferenceId": "28052061", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2017) pmid: 28052061", "Include": "true"}, {"number": "10", "ReferenceId": "29122777", "FullCitation": "Janjigian YY, et al. Cancer Discov (2018) pmid: 29122777", "Include": "true"}, {"number": "11", "ReferenceId": "11004672", "FullCitation": "Tani\u00e8re P, et al. Int. J. Cancer (2000) pmid: 11004672", "Include": "true"}, {"number": "12", "ReferenceId": "21080085", "FullCitation": "Hsu HS, et al. Ann. Surg. Oncol. (2011) pmid: 21080085", "Include": "true"}, {"number": "13", "ReferenceId": "20388212", "FullCitation": "Taghavi N, et al. BMC Cancer (2010) pmid: 20388212", "Include": "true"}, {"number": "14", "ReferenceId": "19488782", "FullCitation": "Cheng TH, et al. J. Cancer Res. Clin. Oncol. (2009) pmid: 19488782", "Include": "true"}, {"number": "15", "ReferenceId": "23159155", "FullCitation": "Yao D, et al. Hum. Pathol. (2013) pmid: 23159155", "Include": "true"}, {"number": "16", "ReferenceId": "23347235", "FullCitation": "Ye Y, et al. Cancer Sci. (2013) pmid: 23347235", "Include": "true"}, {"number": "17", "ReferenceId": "10874665", "FullCitation": "G\u00fcnther T, et al. Mod. Pathol. (2000) pmid: 10874665", "Include": "true"}, {"number": "18", "ReferenceId": "22306053", "FullCitation": "Yang Z, et al. Clin Res Hepatol Gastroenterol (2012) pmid: 22306053", "Include": "true"}, {"number": "19", "ReferenceId": "20975744", "FullCitation": "Cheok CF, et al. Nat Rev Clin Oncol (2011) pmid: 20975744", "Include": "true"}, {"number": "20", "ReferenceId": "23165797", "FullCitation": "Ohnstad HO, et al. Cancer (2013) pmid: 23165797", "Include": "true"}, {"number": "21", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "22", "ReferenceId": "27479139", "FullCitation": "Limm K, et al. PLoS ONE (2016) pmid: 27479139", "Include": "true"}, {"number": "23", "ReferenceId": "25387827", "FullCitation": "Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827", "Include": "true"}, {"number": "24", "ReferenceId": "21356366", "FullCitation": "Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366", "Include": "true"}, {"number": "25", "ReferenceId": "23265702", "FullCitation": "Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702", "Include": "true"}, {"number": "26", "ReferenceId": "19097084", "FullCitation": "Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084", "Include": "true"}, {"number": "27", "ReferenceId": "27068473", "FullCitation": "Marjon K, et al. Cell Rep (2016) pmid: 27068473", "Include": "true"}, {"number": "28", "ReferenceId": "26912361", "FullCitation": "Mavrakis KJ, et al. Science (2016) pmid: 26912361", "Include": "true"}, {"number": "29", "ReferenceId": "26912360", "FullCitation": "Kryukov GV, et al. Science (2016) pmid: 26912360", "Include": "true"}, {"number": "30", "ReferenceId": "25087184", "FullCitation": "Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184", "Include": "true"}, {"number": "31", "ReferenceId": "27929028", "FullCitation": "Wei R, et al. Sci Rep (2016) pmid: 27929028", "Include": "true"}, {"number": "32", "ReferenceId": "27556634", "FullCitation": "Zhao M, et al. BMC Genomics (2016) pmid: 27556634", "Include": "true"}, {"number": "33", "ReferenceId": "19887491", "FullCitation": "Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491", "Include": "true"}, {"number": "34", "ReferenceId": "16778103", "FullCitation": "Marc\u00e9 S, et al. Clin. Cancer Res. (2006) pmid: 16778103", "Include": "true"}, {"number": "35", "ReferenceId": "20500769", "FullCitation": "Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769", "Include": "true"}, {"number": "36", "ReferenceId": "16618867", "FullCitation": "Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867", "Include": "true"}, {"number": "37", "ReferenceId": "21412930", "FullCitation": "Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930", "Include": "true"}, {"number": "38", "ReferenceId": "25426549", "FullCitation": "Li CF, et al. Oncotarget (2014) pmid: 25426549", "Include": "true"}, {"number": "39", "ReferenceId": "26656376", "FullCitation": "He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376", "Include": "true"}, {"number": "40", "ReferenceId": "24969958", "FullCitation": "Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958", "Include": "true"}, {"number": "41", "ReferenceId": "16818274", "FullCitation": "Mirebeau D, et al. Haematologica (2006) pmid: 16818274", "Include": "true"}, {"number": "42", "ReferenceId": "26088413", "FullCitation": "Becker AP, et al. Pathobiology (2015) pmid: 26088413", "Include": "true"}, {"number": "43", "ReferenceId": "27433286", "FullCitation": "Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286", "Include": "true"}, {"number": "44", "ReferenceId": "26910893", "FullCitation": "Bistulfi G, et al. Oncotarget (2016) pmid: 26910893", "Include": "true"}, {"number": "45", "ReferenceId": "25407435", "FullCitation": "Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435", "Include": "true"}, {"number": "46", "ReferenceId": "23816148", "FullCitation": "Maccioni L, et al. BMC Cancer (2013) pmid: 23816148", "Include": "true"}, {"number": "47", "ReferenceId": "26635288", "FullCitation": "Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288", "Include": "true"}, {"number": "48", "ReferenceId": "27960044", "FullCitation": "Lin X, et al. Cancer Sci. (2017) pmid: 27960044", "Include": "true"}, {"number": "49", "ReferenceId": "27994653", "FullCitation": "Zhi L, et al. J Cancer (2016) pmid: 27994653", "Include": "true"}, {"number": "50", "ReferenceId": "23361049", "FullCitation": "Gu F, et al. Br. J. Cancer (2013) pmid: 23361049", "Include": "true"}, {"number": "51", "ReferenceId": "33450196", "FullCitation": "Kalev P, et al. Cancer Cell (2021) pmid: 33450196", "Include": "true"}, {"number": "52", "ReferenceId": "31350521", "FullCitation": "Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521", "Include": "true"}, {"number": "53", "ReferenceId": "31257072", "FullCitation": "Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072", "Include": "true"}, {"number": "54", "ReferenceId": "31287990", "FullCitation": "Srour N, et al. Cancer Cell (2019) pmid: 31287990", "Include": "true"}, {"number": "55", "ReferenceId": "30916320", "FullCitation": "Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320", "Include": "true"}, {"number": "56", "ReferenceId": "35041419", "FullCitation": "Smith CR, et al. J Med Chem (2022) pmid: 35041419", "Include": "true"}, {"number": "57", "ReferenceId": "31040154", "FullCitation": "Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154", "Include": "true"}, {"number": "58", "ReferenceId": "29844120", "FullCitation": "Tang B, et al. Cancer Res. (2018) pmid: 29844120", "Include": "true"}, {"number": "59", "ReferenceId": "24928612", "FullCitation": "Munshi PN, et al. Oncologist (2014) pmid: 24928612", "Include": "true"}, {"number": "60", "ReferenceId": "26751376", "FullCitation": "de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376", "Include": "true"}, {"number": "61", "ReferenceId": "19478948", "FullCitation": "Lubin M, et al. PLoS ONE (2009) pmid: 19478948", "Include": "true"}, {"number": "62", "ReferenceId": "22825330", "FullCitation": "Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330", "Include": "true"}, {"number": "63", "ReferenceId": "22252602", "FullCitation": "Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602", "Include": "true"}, {"number": "64", "ReferenceId": "21301207", "FullCitation": "Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207", "Include": "true"}, {"number": "65", "ReferenceId": "21282358", "FullCitation": "Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358", "Include": "true"}, {"number": "66", "ReferenceId": "17912432", "FullCitation": "Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432", "Include": "true"}, {"number": "67", "ReferenceId": "11987241", "FullCitation": "Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241", "Include": "true"}, {"number": "68", "ReferenceId": "18618081", "FullCitation": "Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081", "Include": "true"}, {"number": "69", "ReferenceId": "35379845", "FullCitation": "Alhalabi O, et al. Nat Commun (2022) pmid: 35379845", "Include": "true"}, {"number": "70", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "71", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "72", "ReferenceId": "16354586", "FullCitation": "McIntyre A, et al. Neoplasia (2005) pmid: 16354586", "Include": "true"}, {"number": "73", "ReferenceId": "19545448", "FullCitation": "Mita H, et al. BMC Cancer (2009) pmid: 19545448", "Include": "true"}, {"number": "74", "ReferenceId": "23099803", "FullCitation": "Birkeland E, et al. Br. J. Cancer (2012) pmid: 23099803", "Include": "true"}, {"number": "75", "ReferenceId": "24874471", "FullCitation": "Chen Y, et al. PLoS ONE (2014) pmid: 24874471", "Include": "true"}, {"number": "76", "ReferenceId": "24816253", "FullCitation": "Wang K, et al. Nat. Genet. (2014) pmid: 24816253", "Include": "true"}, {"number": "77", "ReferenceId": "24816255", "FullCitation": "Kakiuchi M, et al. Nat. Genet. (2014) pmid: 24816255", "Include": "true"}, {"number": "78", "ReferenceId": "22037554", "FullCitation": "Wang K, et al. Nat. Genet. (2011) pmid: 22037554", "Include": "true"}, {"number": "79", "ReferenceId": "23846438", "FullCitation": "Warneke VS, et al. Diagn. Mol. Pathol. (2013) pmid: 23846438", "Include": "true"}, {"number": "80", "ReferenceId": "29808010", "FullCitation": "Wong GS, et al. Nat. Med. (2018) pmid: 29808010", "Include": "true"}, {"number": "81", "ReferenceId": "24935174", "FullCitation": "Qian Z, et al. Genes Chromosomes Cancer (2014) pmid: 24935174", "Include": "true"}, {"number": "82", "ReferenceId": "22315472", "FullCitation": "Deng N, et al. Gut (2012) pmid: 22315472", "Include": "true"}, {"number": "83", "ReferenceId": "30348637", "FullCitation": "Kato S, et al. Clin. Cancer Res. (2018) pmid: 30348637", "Include": "true"}, {"number": "84", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "85", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "86", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "87", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "88", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "89", "ReferenceId": "31118140", "FullCitation": "Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140", "Include": "true"}, {"number": "90", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "91", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "92", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "93", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "94", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "95", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "96", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "97", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "98", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "99", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "100", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "101", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "102", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "103", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "104", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "105", "ReferenceId": "26857262", "FullCitation": "Li X, et al. Cancer Res. (2016) pmid: 26857262", "Include": "true"}, {"number": "106", "ReferenceId": "32141230", "FullCitation": "Cai L, et al. Cancer Commun (Lond) (2020) pmid: 32141230", "Include": "true"}, {"number": "107", "ReferenceId": "33510848", "FullCitation": "Zhao DY, et al. World J Gastrointest Oncol (2021) pmid: 33510848", "Include": "true"}, {"number": "108", "ReferenceId": "33613701", "FullCitation": "Wei XL, et al. Ther Adv Med Oncol (2021) pmid: 33613701", "Include": "true"}, {"number": "109", "ReferenceId": "33687617", "FullCitation": "Wang D, et al. Gastric Cancer (2021) pmid: 33687617", "Include": "true"}, {"number": "110", "ReferenceId": "32165590", "FullCitation": "Yuan C, et al. Aging (Albany NY) (2020) pmid: 32165590", "Include": "true"}, {"number": "111", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "112", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "113", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "114", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "115", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "116", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "117", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "118", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "119", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "120", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "121", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "122", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "123", "ReferenceId": "22992590", "FullCitation": "Nat. Rev. Mol. Cell Biol. (2012) pmid: 22992590", "Include": "true"}, {"number": "124", "ReferenceId": "18662538", "FullCitation": "Cell (2008) pmid: 18662538", "Include": "true"}, {"number": "125", "ReferenceId": "16322555", "FullCitation": "Massagu\u00e9 J, et al. Genes Dev. (2005) pmid: 16322555", "Include": "true"}, {"number": "126", "ReferenceId": "10980615", "FullCitation": "Mor\u00e9n A, et al. Oncogene (2000) pmid: 10980615", "Include": "true"}, {"number": "127", "ReferenceId": "10781087", "FullCitation": "Xu J, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10781087", "Include": "true"}, {"number": "128", "ReferenceId": "10485843", "FullCitation": "Luo K, et al. Genes Dev. (1999) pmid: 10485843", "Include": "true"}, {"number": "129", "ReferenceId": "10871368", "FullCitation": "Jones JB, et al. Nucleic Acids Res. (2000) pmid: 10871368", "Include": "true"}, {"number": "130", "ReferenceId": "11196171", "FullCitation": "Fink SP, et al. Cancer Res. (2001) pmid: 11196171", "Include": "true"}, {"number": "131", "ReferenceId": "14715079", "FullCitation": "De Bosscher K, et al. Biochem. J. (2004) pmid: 14715079", "Include": "true"}, {"number": "132", "ReferenceId": "9214508", "FullCitation": "Shi Y, et al. Nature (1997) pmid: 9214508", "Include": "true"}, {"number": "133", "ReferenceId": "10340381", "FullCitation": "Miyaki M, et al. Oncogene (1999) pmid: 10340381", "Include": "true"}, {"number": "134", "ReferenceId": "17994767", "FullCitation": "Prokova V, et al. Biochemistry (2007) pmid: 17994767", "Include": "true"}, {"number": "135", "ReferenceId": "11274206", "FullCitation": "Wu JW, et al. J. Biol. Chem. (2001) pmid: 11274206", "Include": "true"}, {"number": "136", "ReferenceId": "19139564", "FullCitation": "Ding L, et al. J. Clin. Invest. (2009) pmid: 19139564", "Include": "true"}, {"number": "137", "ReferenceId": "14647410", "FullCitation": "Kuang C, et al. Oncogene (2004) pmid: 14647410", "Include": "true"}, {"number": "138", "ReferenceId": "11265759", "FullCitation": "Watanabe M, et al. EMBO Rep. (2000) pmid: 11265759", "Include": "true"}, {"number": "139", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "140", "ReferenceId": "24293293", "FullCitation": "Jiao Y, et al. J. Pathol. (2014) pmid: 24293293", "Include": "true"}, {"number": "141", "ReferenceId": "25536104", "FullCitation": "Churi CR, et al. PLoS ONE (2014) pmid: 25536104", "Include": "true"}, {"number": "142", "ReferenceId": "24821835", "FullCitation": "Liu X, et al. Clin. Chem. (2014) pmid: 24821835", "Include": "true"}, {"number": "143", "ReferenceId": "14647445", "FullCitation": "Maru D, et al. Oncogene (2004) pmid: 14647445", "Include": "true"}, {"number": "144", "ReferenceId": "26336083", "FullCitation": "Wang K, et al. Oncologist (2015) pmid: 26336083", "Include": "true"}, {"number": "145", "ReferenceId": "17349581", "FullCitation": "Izeradjene K, et al. Cancer Cell (2007) pmid: 17349581", "Include": "true"}, {"number": "146", "ReferenceId": "17114584", "FullCitation": "Bardeesy N, et al. Genes Dev. (2006) pmid: 17114584", "Include": "true"}, {"number": "147", "ReferenceId": "26253305", "FullCitation": "Springer S, et al. Gastroenterology (2015) pmid: 26253305", "Include": "true"}, {"number": "148", "ReferenceId": "19584151", "FullCitation": "Blackford A, et al. Clin. Cancer Res. (2009) pmid: 19584151", "Include": "true"}, {"number": "149", "ReferenceId": "26861460", "FullCitation": "Yan P, et al. Clin. Cancer Res. (2016) pmid: 26861460", "Include": "true"}, {"number": "150", "ReferenceId": "25681512", "FullCitation": "Kozak MM, et al. J. Clin. Pathol. (2015) pmid: 25681512", "Include": "true"}, {"number": "151", "ReferenceId": "23104212", "FullCitation": "Roth AD, et al. J. Natl. Cancer Inst. (2012) pmid: 23104212", "Include": "true"}, {"number": "152", "ReferenceId": "24618609", "FullCitation": "Davison JM, et al. Am. J. Surg. Pathol. (2014) pmid: 24618609", "Include": "true"}, {"number": "153", "ReferenceId": "15033661", "FullCitation": "Kim YH, et al. Ann. Oncol. (2004) pmid: 15033661", "Include": "true"}, {"number": "154", "ReferenceId": "11234879", "FullCitation": "Xiangming C, et al. Clin. Cancer Res. (2001) pmid: 11234879", "Include": "true"}, {"number": "155", "ReferenceId": "25634752", "FullCitation": "Singhi AD, et al. Am. J. Surg. Pathol. (2015) pmid: 25634752", "Include": "true"}, {"number": "156", "ReferenceId": "12060625", "FullCitation": "Natsugoe S, et al. Clin. Cancer Res. (2002) pmid: 12060625", "Include": "true"}, {"number": "157", "ReferenceId": "23022998", "FullCitation": "de Kruijf EM, et al. Ann. Oncol. (2013) pmid: 23022998", "Include": "true"}, {"number": "158", "ReferenceId": "25032733", "FullCitation": "Shipitsin M, et al. Br. J. Cancer (2014) pmid: 25032733", "Include": "true"}, {"number": "159", "ReferenceId": "35393542", "FullCitation": "Shi C, et al. Oncogene (2022) pmid: 35393542", "Include": "true"}, {"number": "160", "ReferenceId": "35274815", "FullCitation": "Park JW, et al. Cancer Med (2022) pmid: 35274815", "Include": "true"}, {"number": "161", "ReferenceId": "28534865", "FullCitation": "Ormanns S, et al. Int J Mol Sci (2017) pmid: 28534865", "Include": "true"}, {"number": "162", "ReferenceId": "34002944", "FullCitation": "Fei N, et al. Clin Transl Sci (2021) pmid: 34002944", "Include": "true"}, {"number": "163", "ReferenceId": "22377565", "FullCitation": "Bachet JB, et al. Ann. Oncol. (2012) pmid: 22377565", "Include": "true"}, {"number": "164", "ReferenceId": "28577946", "FullCitation": "Ziemke M, et al. Lung Cancer (2017) pmid: 28577946", "Include": "true"}, {"number": "165", "ReferenceId": "32897998", "FullCitation": "Kassardjian A, et al. Pancreas (2020) pmid: 32897998", "Include": "true"}, {"number": "166", "ReferenceId": "33667587", "FullCitation": "Pen SL, et al. Radiother Oncol (2021) pmid: 33667587", "Include": "true"}, {"number": "167", "ReferenceId": "9811934", "FullCitation": "Houlston R, et al. Hum. Mol. Genet. (1998) pmid: 9811934", "Include": "true"}, {"number": "168", "ReferenceId": "10764709", "FullCitation": "Woodford_Richens K, et al. Gut (2000) pmid: 10764709", "Include": "true"}, {"number": "169", "ReferenceId": "15235019", "FullCitation": "Howe JR, et al. J. Med. Genet. (2004) pmid: 15235019", "Include": "true"}, {"number": "170", "ReferenceId": "22171123", "FullCitation": "Brosens LA, et al. World J. Gastroenterol. (2011) pmid: 22171123", "Include": "true"}, {"number": "171", "ReferenceId": "27854360", "FullCitation": "Kalia SS, et al. Genet. Med. (2017) pmid: 27854360", "Include": "true"}, {"number": "172", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "173", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "174", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "175", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "176", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "177", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "178", "ReferenceId": "19160092", "FullCitation": "Sengpiel C, et al. Cancer Invest. (2009) pmid: 19160092", "Include": "true"}, {"number": "179", "ReferenceId": "16538517", "FullCitation": "P\u00fchringer_Oppermann F, et al. J. Cancer Res. Clin. Oncol. (2006) pmid: 16538517", "Include": "true"}, {"number": "180", "ReferenceId": "23969480", "FullCitation": "Lee HE, et al. Pathobiology (2014) pmid: 23969480", "Include": "true"}, {"number": "181", "ReferenceId": "23613399", "FullCitation": "Sezer C, et al. J BUON () pmid: 23613399", "Include": "true"}, {"number": "182", "ReferenceId": "8664030", "FullCitation": "Victorzon M, et al. Eur. J. Cancer (1996) pmid: 8664030", "Include": "true"}, {"number": "183", "ReferenceId": "21116760", "FullCitation": "Gon\u00e7alves AR, et al. Pathol. Oncol. Res. (2011) pmid: 21116760", "Include": "true"}, {"number": "184", "ReferenceId": "17760650", "FullCitation": "Han U, et al. Dis. Esophagus (2007) pmid: 17760650", "Include": "true"}, {"number": "185", "ReferenceId": "19941080", "FullCitation": "Yamasaki M, et al. Ann. Surg. Oncol. (2010) pmid: 19941080", "Include": "true"}, {"number": "186", "ReferenceId": "23285001", "FullCitation": "Liu X, et al. PLoS ONE (2012) pmid: 23285001", "Include": "true"}, {"number": "187", "ReferenceId": "18751407", "FullCitation": "Wiksten JP, et al. Anticancer Res. () pmid: 18751407", "Include": "true"}, {"number": "188", "ReferenceId": "15254976", "FullCitation": "Migliavacca M, et al. J. Cell. Physiol. (2004) pmid: 15254976", "Include": "true"}, {"number": "189", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "190", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "191", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "192", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "193", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "194", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "195", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "196", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "197", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "198", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "199", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "200", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "201", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "202", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "203", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "204", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "205", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "206", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "207", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "208", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "209", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "210", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "211", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "212", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "213", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "214", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "215", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "216", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "217", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "218", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "219", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "220", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "221", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "222", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "223", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "224", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "225", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "226", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "227", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "228", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "229", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "230", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "231", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "232", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "233", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "234", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "235", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "236", "ReferenceId": "19621725", "FullCitation": "Gu M, et al. Hepatogastroenterology () pmid: 19621725", "Include": "true"}, {"number": "237", "ReferenceId": "22866067", "FullCitation": "Sasaki S, et al. Oncol Lett (2011) pmid: 22866067", "Include": "true"}, {"number": "238", "ReferenceId": "10070967", "FullCitation": "Fleisher AS, et al. Cancer Res. (1999) pmid: 10070967", "Include": "true"}, {"number": "239", "ReferenceId": "21045259", "FullCitation": "Vasavi M, et al. Cancer Biomark (2010) pmid: 21045259", "Include": "true"}, {"number": "240", "ReferenceId": "24035280", "FullCitation": "Zhang LH, et al. Pathol. Res. Pract. (2013) pmid: 24035280", "Include": "true"}, {"number": "241", "ReferenceId": "26137290", "FullCitation": "Zhu L, et al. Mol Clin Oncol (2015) pmid: 26137290", "Include": "true"}, {"number": "242", "ReferenceId": "9892201", "FullCitation": "Leung SY, et al. Cancer Res. (1999) pmid: 9892201", "Include": "true"}, {"number": "243", "ReferenceId": "26078567", "FullCitation": "Seo JY, et al. World J. Gastroenterol. (2015) pmid: 26078567", "Include": "true"}, {"number": "244", "ReferenceId": "31513484", "FullCitation": "Pietrantonio F, et al. J. Clin. Oncol. (2019) pmid: 31513484", "Include": "true"}, {"number": "245", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "246", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "247", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "248", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "249", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "250", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "251", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "252", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "253", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "254", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "255", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "256", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "257", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "258", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "259", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "260", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "261", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "262", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "263", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "264", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "265", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "266", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "267", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "268", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "269", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "270", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "271", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "272", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "273", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "274", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "275", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "276", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "277", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "278", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "279", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "280", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "281", "ReferenceId": "10537333", "FullCitation": "Xing EP, et al. Clin. Cancer Res. (1999) pmid: 10537333", "Include": "true"}, {"number": "282", "ReferenceId": "22920630", "FullCitation": "Hao JJ, et al. BMC Cancer (2012) pmid: 22920630", "Include": "true"}, {"number": "283", "ReferenceId": "21757289", "FullCitation": "Rumiato E, et al. Cancer Lett. (2011) pmid: 21757289", "Include": "true"}, {"number": "284", "ReferenceId": "17060721", "FullCitation": "Kim SG, et al. Korean J Gastroenterol (2006) pmid: 17060721", "Include": "true"}, {"number": "285", "ReferenceId": "7845688", "FullCitation": "Liu Q, et al. Oncogene (1995) pmid: 7845688", "Include": "true"}, {"number": "286", "ReferenceId": "9212218", "FullCitation": "Muzeau F, et al. Int. J. Cancer (1997) pmid: 9212218", "Include": "true"}, {"number": "287", "ReferenceId": "18241037", "FullCitation": "Chen J, et al. Int. J. Cancer (2008) pmid: 18241037", "Include": "true"}, {"number": "288", "ReferenceId": "9333024", "FullCitation": "Hayashi K, et al. Oncogene (1997) pmid: 9333024", "Include": "true"}, {"number": "289", "ReferenceId": "16299787", "FullCitation": "Koppert LB, et al. J Surg Oncol (2005) pmid: 16299787", "Include": "true"}, {"number": "290", "ReferenceId": "22450065", "FullCitation": "Bandla S, et al. Ann. Thorac. Surg. (2012) pmid: 22450065", "Include": "true"}, {"number": "291", "ReferenceId": "18519675", "FullCitation": "Nancarrow DJ, et al. Cancer Res. (2008) pmid: 18519675", "Include": "true"}, {"number": "292", "ReferenceId": "23803092", "FullCitation": "Xiong HL, et al. Asian Pac. J. Cancer Prev. (2013) pmid: 23803092", "Include": "true"}, {"number": "293", "ReferenceId": "12060614", "FullCitation": "Lee TL, et al. Clin. Cancer Res. (2002) pmid: 12060614", "Include": "true"}, {"number": "294", "ReferenceId": "21849808", "FullCitation": "Alves MK, et al. Pathobiology (2011) pmid: 21849808", "Include": "true"}, {"number": "295", "ReferenceId": "22206050", "FullCitation": "Shi J, et al. Am J Cancer Res (2012) pmid: 22206050", "Include": "true"}, {"number": "296", "ReferenceId": "11819820", "FullCitation": "He XS, et al. World J. Gastroenterol. (2001) pmid: 11819820", "Include": "true"}, {"number": "297", "ReferenceId": "12890389", "FullCitation": "Tang S, et al. Chin. Med. J. (2003) pmid: 12890389", "Include": "true"}, {"number": "298", "ReferenceId": "18410530", "FullCitation": "Huang Y, et al. J. Cell. Mol. Med. (2009) pmid: 18410530", "Include": "true"}, {"number": "299", "ReferenceId": "23408900", "FullCitation": "Achyut BR, et al. PLoS Genet. (2013) pmid: 23408900", "Include": "true"}, {"number": "300", "ReferenceId": "12208744", "FullCitation": "Tokugawa T, et al. Cancer Res. (2002) pmid: 12208744", "Include": "true"}, {"number": "301", "ReferenceId": "18269647", "FullCitation": "Fujiwara S, et al. Dis. Esophagus (2008) pmid: 18269647", "Include": "true"}, {"number": "302", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "303", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "304", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "305", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "306", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "307", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "308", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "309", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "310", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "311", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "312", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "313", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "314", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "315", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "316", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "317", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "318", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "319", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "320", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "321", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "322", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "323", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "324", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "325", "ReferenceId": "16203743", "FullCitation": "Huang G, et al. Hum. Mol. Genet. (2005) pmid: 16203743", "Include": "true"}, {"number": "326", "ReferenceId": "19242095", "FullCitation": "Banck MS, et al. Epigenetics (2009) pmid: 19242095", "Include": "true"}, {"number": "327", "ReferenceId": "9671742", "FullCitation": "Collins C, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9671742", "Include": "true"}, {"number": "328", "ReferenceId": "11245413", "FullCitation": "Nonet GH, et al. Cancer Res. (2001) pmid: 11245413", "Include": "true"}, {"number": "329", "ReferenceId": "17266044", "FullCitation": "Li P, et al. Int. J. Cancer (2007) pmid: 17266044", "Include": "true"}, {"number": "330", "ReferenceId": "22593193", "FullCitation": "Vendrell JA, et al. Cancer Res. (2012) pmid: 22593193", "Include": "true"}, {"number": "331", "ReferenceId": "25031722", "FullCitation": "Li J, et al. Int J Clin Exp Pathol (2014) pmid: 25031722", "Include": "true"}, {"number": "332", "ReferenceId": "22843878", "FullCitation": "Rahman MT, et al. Anticancer Res. (2012) pmid: 22843878", "Include": "true"}, {"number": "333", "ReferenceId": "15701848", "FullCitation": "Yang SH, et al. Clin. Cancer Res. (2005) pmid: 15701848", "Include": "true"}, {"number": "334", "ReferenceId": "25202062", "FullCitation": "Shida A, et al. Anticancer Res. (2014) pmid: 25202062", "Include": "true"}, {"number": "335", "ReferenceId": "15476264", "FullCitation": "Rooney PH, et al. J. Pathol. (2004) pmid: 15476264", "Include": "true"}, {"number": "336", "ReferenceId": "22815235", "FullCitation": "Szczyrba J, et al. Int. J. Cancer (2013) pmid: 22815235", "Include": "true"}, {"number": "337", "ReferenceId": "24853183", "FullCitation": "Geppert CI, et al. Br. J. Cancer (2014) pmid: 24853183", "Include": "true"}, {"number": "338", "ReferenceId": "15897688", "FullCitation": "Toncheva D, et al. Tumour Biol. () pmid: 15897688", "Include": "true"}, {"number": "339", "ReferenceId": "21483406", "FullCitation": "Mao XG, et al. Lab. Invest. (2011) pmid: 21483406", "Include": "true"}, {"number": "340", "ReferenceId": "18193277", "FullCitation": "Schipf A, et al. Virchows Arch. (2008) pmid: 18193277", "Include": "true"}, {"number": "341", "ReferenceId": "17572303", "FullCitation": "Quinlan KG, et al. Biochim. Biophys. Acta (2007) pmid: 17572303", "Include": "true"}, {"number": "342", "ReferenceId": "17259635", "FullCitation": "Krig SR, et al. J. Biol. Chem. (2007) pmid: 17259635", "Include": "true"}, {"number": "343", "ReferenceId": "17130829", "FullCitation": "Cowger JJ, et al. Oncogene (2007) pmid: 17130829", "Include": "true"}, {"number": "344", "ReferenceId": "20661224", "FullCitation": "Krig SR, et al. Oncogene (2010) pmid: 20661224", "Include": "true"}, {"number": "345", "ReferenceId": "21059223", "FullCitation": "Thollet A, et al. Mol. Cancer (2010) pmid: 21059223", "Include": "true"}, {"number": "346", "ReferenceId": "24973012", "FullCitation": "Nguyen NT, et al. Mol Oncol (2014) pmid: 24973012", "Include": "true"}, {"number": "347", "ReferenceId": "24962896", "FullCitation": "Frietze S, et al. BMC Genomics (2014) pmid: 24962896", "Include": "true"}, {"number": "348", "ReferenceId": "22728437", "FullCitation": "Littlepage LE, et al. Cancer Discov (2012) pmid: 22728437", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_09_20 23:25:22", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "621x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "STOMACH", "disease_ontology": "Stomach adenocarcinoma (NOS)", "flowcell_analysis": "2000023598", "gender": "male", "pathology_diagnosis": "Adenocarcinoma", "percent_tumor_nuclei": "20", "pipeline_version": "v3.14.0", "purity_assessment": "42.1", "specimen": "ORD_1452967_01*US1393440.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1452967_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Stomach", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "648.9", "name": "SQ_US1393440.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4132", "cds_effect": "1517G>A", "depth": "547", "equivocal": "false", "functional_effect": "missense", "gene": "CBL", "percent_reads": "41.32", "position": "chr11:119155764", "protein_effect": "R506Q", "status": "unknown", "strand": "+", "transcript": "NM_005188", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.4917", "cds_effect": "131A>G", "depth": "604", "equivocal": "false", "functional_effect": "missense", "gene": "PTCH1", "percent_reads": "49.17", "position": "chr9:98278972", "protein_effect": "E44G", "status": "unknown", "strand": "_", "transcript": "NM_001083603", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.3281", "cds_effect": "1813G>A", "depth": "640", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "32.81", "position": "chr2:29519758", "protein_effect": "D605N", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.4871", "cds_effect": "743C>G", "depth": "542", "equivocal": "false", "functional_effect": "missense", "gene": "FANCC", "percent_reads": "48.71", "position": "chr9:97897728", "protein_effect": "P248R", "status": "unknown", "strand": "_", "transcript": "NM_000136", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.4156", "cds_effect": "964G>A", "depth": "320", "equivocal": "false", "functional_effect": "missense", "gene": "NKX2_1", "percent_reads": "41.56", "position": "chr14:36986635", "protein_effect": "G322S", "status": "unknown", "strand": "_", "transcript": "NM_003317", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.4706", "cds_effect": "3907C>T", "depth": "391", "equivocal": "false", "functional_effect": "missense", "gene": "PTCH1", "percent_reads": "47.06", "position": "chr9:98209631", "protein_effect": "R1303C", "status": "unknown", "strand": "_", "transcript": "NM_000264", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.1335", "cds_effect": "782G>A", "depth": "412", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "13.35", "position": "chr17:7577499", "protein_effect": "S261N", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.6497", "cds_effect": "1445C>T", "depth": "334", "equivocal": "false", "functional_effect": "missense", "gene": "SUFU", "percent_reads": "64.97", "position": "chr10:104389902", "protein_effect": "P482L", "status": "unknown", "strand": "+", "transcript": "NM_016169", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.3173", "cds_effect": "1136G>A", "depth": "394", "equivocal": "false", "functional_effect": "missense", "gene": "PARP3", "percent_reads": "31.73", "position": "chr3:51980219", "protein_effect": "R379Q", "status": "unknown", "strand": "+", "transcript": "NM_005485", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"allele_fraction": "0.291", "cds_effect": "1138G>T", "depth": "677", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK3", "percent_reads": "29.1", "position": "chr15:88678398", "protein_effect": "A380S", "status": "unknown", "strand": "_", "transcript": "NM_002530", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "12", "equivocal": "false", "gene": "PIK3C2G", "number_of_exons": "31 of 31", "position": "chr12:18435015_18800962", "ratio": "3.12", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"copy_number": "43", "equivocal": "false", "gene": "MDM2", "number_of_exons": "11 of 11", "position": "chr12:69153996_69277205", "ratio": "9.32", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21853212_21998002", "ratio": "0.68", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "MTAP", "number_of_exons": "6 of 8", "position": "chr9:21816677_21862058", "ratio": "0.7", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"copy_number": "12", "equivocal": "false", "gene": "KRAS", "number_of_exons": "5 of 5", "position": "chr12:25344730_25448217", "ratio": "3.03", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"copy_number": "10", "equivocal": "false", "gene": "ZNF217", "number_of_exons": "4 of 4", "position": "chr20:52188273_52199365", "ratio": "2.75", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "SMAD4", "number_of_exons": "11 of 11", "position": "chr18:48426308_48784036", "ratio": "0.67", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:21998748_22101832", "ratio": "0.68", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}]}, "rearrangements": {"rearrangement": {"description": "AKT3(NM_181690) rearrangement intron 13", "equivocal": "false", "in_frame": "unknown", "other_gene": "PHACTR1", "pos1": "chr1:243657118_243657349", "pos2": "chr6:13191184_13191309", "status": "unknown", "supporting_read_pairs": "10", "targeted_gene": "AKT3", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1393440.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.62", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}